Focused On-demand Library for Ectonucleotide pyrophosphatase/phosphodiesterase family member 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9UJA9

UPID:

ENPP5_HUMAN

Alternative names:

Alternative UPACC:

Q9UJA9; Q5TFV2; Q6UX49

Background:

Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 (ENPP5) is a unique enzyme with the ability to hydrolyze NAD while showing no activity towards nucleotide di- and triphosphates. Unlike other members of its family, it does not possess lysopholipase D activity, suggesting a specialized function. ENPP5's role in neuronal cell communication highlights its importance in the nervous system.

Therapeutic significance:

Understanding the role of Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 could open doors to potential therapeutic strategies. Its specific function in neuronal communication positions it as a key player in neurobiological research, with implications for treating neurological disorders.